The recorded searches did not identify a qualifying combination trial. That prevents a reliable claim about fat loss, muscle, recovery or safety. The CJC-1295 and ipamorelin reports concern different products and populations; the combination overview explains the distinction.
The recorded searches identified no combination trial
An October 22, 2026 Europe PMC search returned 23 indexed records, including reviews, analytical reports and preprints; none reported a clinical trial administering this combination [2]. The current ClinicalTrials.gov combination query returned no studies [1]. These searches do not establish that every unpublished experiment is known; they establish the limits of the located clinical evidence.
Mechanistic plausibility cannot supply a measured treatment effect. The located studies of each ingredient alone should be read on their own terms; they cannot establish how the mixture behaves in people.
| Compound | Best human study | People | Outcome measured | Result |
|---|---|---|---|---|
| CJC-1295 (DAC form) | Teichman 2006, two randomized trials | FDA’s 63 reported exposures include overlapping reports | Growth hormone and IGF-1 levels | Raised for days; no health outcome measured |
| CJC-1295 | ConjuChem phase 2, HIV-related belly fat | 192 per press reports | Visceral fat | Terminated; never published |
| Ipamorelin | Beck 2014, randomized trial after bowel surgery | 117 enrolled | Time to first tolerated meal | Not significant (p = 0.15) |
| Ipamorelin | Helsinn phase 2 (NCT01280344) | 320 enrolled | Recovery of gut function | Completed 2013; no results posted |
| CJC-1295 + ipamorelin | No qualifying trial located | Not established | Not established | No reliable effect size |
Sources: PubMed; FDA PCAC briefings, October and December 2024; ClinicalTrials.gov.
Hormone and protein changes are different from clinical benefit
CJC-1295 did what it was designed to do: raise growth hormone for a long time. In two small randomized trials in healthy adults aged 21 to 61, one injection raised growth hormone 2- to 10-fold for 6 days or more, and IGF-1 1.5- to 3-fold for 9 to 11 days [3]. Its half-life was 5.8 to 8.1 days.
The 2006 hormone reports do not establish a clinical body-composition or wellness benefit. A 2009report analyzed serum proteins in 11 men from the Ionescu cohort; it adds biomarker analysis rather than an independent treatment-outcome trial [13]. FDA’s 63-exposure summary includes overlapping published reports [7].
A terminated CJC efficacy study has no posted results
FDA’s review describes a terminated phase 2 efficacy trial without published outcome data. FDA's account, based on press reports rather than a paper, describes a phase 2 trial by ConjuChem in people with HIV-associated fat build-up, with 192 people randomized to CJC-1295 or placebo [7].
FDA’s press-based account describes a heart attack two hours after an 11th weekly dose and death about an hour later. The attending physician attributed it to undiagnosed coronary artery disease. The study was terminated, and its data have not been published [7]. The trial's ClinicalTrials.gov entry lists ConjuChem, a 12-week design and a planned 120 participants, with the status "terminated" and no results [9]. Whether CJC-1295 reduced belly fat in those people is unknown.
Ipamorelin missed its one published efficacy goal
Ipamorelin's selected published evidence includes a dosing study and a postoperative efficacy trial, neither about fat, muscle or aging. The 1999 study gave 48 healthy men a single infusion to measure hormone response [4]. The 2014 phase 2 trial tested whether ipamorelin by vein sped recovery after bowel surgery. Median time to a tolerated meal was 25.3 hours against 32.6 hours on placebo, a difference that was not significant (p = 0.15) [5].
A larger phase 2 trial by Helsinn Therapeutics enrolled 320 people and completed its primary outcome phase in June 2013 and the overall study in May 2014, but no results are posted in the registry as of this update [10]. Its safety picture, including fluid retention, is in does ipamorelin cause water retention.
"No-DAC" CJC-1295 is not the molecule that was studied
The CJC-1295 in the published studies had DAC attached, a chemical add-on that binds to blood albumin and keeps the peptide active for days. Products sold as "CJC-1295 no DAC" are a different molecule whose human PK is not established by the DAC studies. FDA treats the two as distinct active ingredients and notes that the studies it found refer to the DAC form [7].
FDA also flags the naming itself. It says inconsistent naming of CJC-1295 products is a safety risk because a patient "may be dosed with a different BDS than the physician ordered" [7]. If you are offered CJC-1295, ask which form it is. The answer tells you whether even the hormone data apply to it.
A higher hormone level is not the same as results
A growth-hormone or IGF-1 change is a measured biomarker result, but does not by itself establish clinical benefit. The way to know a growth-hormone-releasing drug does something useful is a trial that measures the outcome. Tesamorelin, an FDA-approved GHRH analog, had one: in a 26-week randomized trial of 412 people with HIV and excess belly fat, visceral fat fell 15.2% on the drug and rose 5.0% on placebo [6].
That is the level of evidence the CJC-1295 and ipamorelin pair doesn't have, for any outcome, in any group of people. How CJC-1295 compares with the approved drug is covered in CJC-1295 vs tesamorelin, and with sermorelin in CJC-1295 vs sermorelin.
Before-and-after posts are not trials
Uncontrolled before-and-after observations cannot separate a treatment effect from other changes, selection, expectations or the passage of time. Check whether a claimed result came from the exact product and population, with an appropriate comparison.
Both peptides are also banned in tested sport: WADA's Prohibited List names CJC-1295 and ipamorelin under S2.2.4 [11]. Side effects and FDA's concerns are in is CJC-1295 and ipamorelin safe. How this site reads trial and FDA records is set out in how we check.
A current observational registry, NCT07717866, lists 52 actual participants in a multimodal veterans program and names ipamorelin among several physiological-supplementation options. It has no posted results and does not isolate ipamorelin, establish its route-specific safety or test this CJC combination [12].
Sackmann-Sala’s 2009 serum-protein report used 11 healthy men from an earlier CJC cohort. It measured candidate protein biomarkers, not muscle growth, fat loss or functional recovery [13]. Counting that publication as a new independent trial would overstate the evidence.